J7639 HCPCS Level II code: Dornase alfa, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram
J7639 is the HCPCS code for “Dornase alfa, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J7639Dornase alfa, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram
Short description: Dornase alfa non-comp unit
HCPCS · United States
Notes for J7639
As CMS prints them, with any note J7639 takes from the headings above it.
Note
- CMS processing note 0135: MEDICARE BENEFIT POLICY MANUAL, PUB 100.2, CHAPTER 15, SECTION 110.3 (100.02,15,110.3).
Medicare details
The indicators CMS publishes with J7639 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Drugs Administered through DME
- Added
- Jan 1, 2000
Where J7639 sits
- 1J codesDrugs administered other than orally
- 2Active code J7639Dornase alfa, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J7639 mean?
J7639 is the HCPCS code for “Dornase alfa, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J7639?
CMS lists J7639’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J7639
All J codesJ7633Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 0.25 milligramJ7634Budesonide, inhalation solution, compounded product, administered through dme, concentrated form, per 0.25 milligramJ7635Atropine, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7636Atropine, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7637Dexamethasone, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7638Dexamethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7640Formoterol, inhalation solution, compounded product, administered through dme, unit dose form, 12 microgramsJ7641Flunisolide, inhalation solution, compounded product, administered through dme, unit dose, per milligramJ7642Glycopyrrolate, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7643Glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7644Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligramJ7645Ipratropium bromide, inhalation solution, compounded product, administered through dme, unit dose form, per milligram